We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

ACTIPH Water

Status: Active

Jul 20th 2020 - Aug 20th 2020

ACTIPH is a company that manufactures high-alkaline, ionised water having a 'Power of Hydrogen' (pH) of 9.8 providing the required hydration to people who live an active lifestyle. The company's UK listings include Tesco, Ocado, Harrods, Sainsbury's, Selfridges, Planet Organic, and Wholefoods among others. It also exports to 11 countries globally. By April 2020, the company sold over 1.35 million units and amassed 26,300 social media followers. Alkaline water has become one of the fastest-growing categories globally with sales of $883 million+ in 2018. By 2023, the market is expected to exceed $4.3 billion. ACTIPH aims to be a leading contender in this segment. Its vision is to lead the growth of alkaline waters across Europe and the Middle East. It will use the investment to increase its sales to drive further distribution across Europe, invest in marketing to drive penetration and educate on the health benefits of its products, increase production capability, and accelerate new product development.

read more read less

ACTIPH Water Rating Review

Pitch rating powered by CROWDRATING

Rated on 22/07/2020

Pitch Rated

69%

overall

Management

84%

Product

77%

Investment

45%

Log in to view amount pledged

    Log in to view target

    £7,001,952
    pre-money valuation

    6.67%
    equity available

    834
    investors

    £1,439
    pledge per investor

    05/05/2015
    incorporated 9 years

    £8.79
    share price

    Previous Funding rounds
    20 Jul 20 Crowdcube £1,200,004 / 240% 68.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 84%

Skills 91%
ACTIPH Water is managed by a diverse and skilled team that includes specialists in entrepreneurship, retail, science, accounts, and marketing. The founder is an award-winning entrepreneur with sales and marketing skills. He is the winner of the 'Great British Entrepreneur of the Year' award in 2018 for Scotland & NI, and was in the 'Maserati 100 Most Disruptive Entrepreneurs' in the UK. The CEO has a flair for management, shopper marketing, customer development, and e-commerce. He has been instrumental in the FMCG sector and held senior positions at Director levels. The COO is a proficient research and development expert and has been key to the development of the ACTIPH product. Also, the company has appointed three Account Managers who specialise in sales, account management and communication.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £7,001,952
    pre-money valuation

    6.67%
    equity available

    834
    investors

    £1,439
    pledge per investor

    05/05/2015
    incorporated 9 years

    £8.79
    share price

    Previous Funding rounds
    20 Jul 20 Crowdcube £1,200,004 / 240% 68.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph